Acousia Therapeutics GmbH has announced that they have successfully enrolled 50% of patients in their ongoing Phase 2 clinical trial, the PROHEAR Study. The study is evaluating the effectiveness of ACOU085 (INN: bimokalner) in preventing cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a commonly used drug in cancer treatment and has been…
No responses yet